<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30841663</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-9624</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</Title><ISOAbbreviation>Zhonghua Yu Fang Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)].</ArticleTitle><Pagination><StartPage>258</StartPage><EndPage>261</EndPage><MedlinePgn>258-261</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-9624.2019.03.004</ELocationID><Abstract><AbstractText><b>Objective:</b> To evaluate the post-marketing safety of inactivated Enterovirus type 71 (EV-A71) vaccine (human diploid cell) . <b>Methods:</b> A total of 20 191 healthy children aged 6 to 59 months were invited to receive 2 doses of EV-A71 vaccine in Zhejiang Province from September 2016 to December 2017. Child caregivers were followed up on the 4(th) or 5(th) day after each EV-A71 vaccination, and the incidence of local, systemic, and other adverse events within 3 days after vaccination was recorded to assess vaccine safety. Describe the differences in adverse events among children with different characteristics. <b>Results:</b> A total of 32 230 doses were observed in this study, of which 20 191 and 12 039 were vaccinated for the first and the second dose, respectively; and the incidence of adverse events within 3 days was 2.045% (413 doses) and 1.611% (194 doses), respectively. After the first and the second dose, the number of systemic adverse events was the highest, 371 and 175 cases, respectively, with an incidence of 1.837% and 1.454%, respectively; the number of local adverse events was the lowest, 14 and 2 doses, respectively, with an incidence of 0.069% and 0.017%. Local adverse events occurred after vaccination were generally mild, and only 2 patients had level of 3; among the systemic adverse events, 39 patients had a fever level of 3 or higher, accounting for 8.2% of the total fever. Most of the symptoms in the local adverse events did not require treatment, only 3 cases of vaccination site rash and 2 cases of pruritus were self-purchased drugs or outpatient treatment; except for 5 cases of fever, the other symptoms were not hospitalized in the case of systemic adverse events. <b>Conclusion:</b> The incidence of adverse events within 3 days after vaccination with EV-A71 vaccine was low in children, mainly systemic adverse events, and the prognosis was good.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>L Z</ForeName><Initials>LZ</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Zhejiang Provincal Center for Disease Control and Prevention, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>X J</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>S Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Z P</ForeName><Initials>ZP</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yu Fang Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7904962</NlmUniqueID><ISSNLinking>0253-9624</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004171" MajorTopicYN="N">Diploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x8bc4;&#x4ef7;&#x80a0;&#x9053;&#x75c5;&#x6bd2;A71&#x578b;&#xff08;EV-A71&#xff09;&#x706d;&#x6d3b;&#x75ab;&#x82d7;&#xff08;EV-A71&#x75ab;&#x82d7;&#xff09;&#xff08;&#x4eba;&#x4e8c;&#x500d;&#x4f53;&#x7ec6;&#x80de;&#xff09;&#x4e0a;&#x5e02;&#x540e;&#x63a5;&#x79cd;&#x7684;&#x5b89;&#x5168;&#x6027;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x4ee5;2016&#x5e74;9&#x6708;&#x81f3;2017&#x5e74;12&#x6708;&#x5728;&#x6d59;&#x6c5f;&#x7701;&#x9884;&#x9632;&#x63a5;&#x79cd;&#x95e8;&#x8bca;&#x63a5;&#x79cd;EV-A71&#x75ab;&#x82d7;&#x7684;6~59&#x6708;&#x9f84;&#x5065;&#x5eb7;&#x513f;&#x7ae5;&#x4f5c;&#x4e3a;&#x7814;&#x7a76;&#x5bf9;&#x8c61;&#xff0c;&#x5171;20 191&#x540d;&#x3002;&#x5728;&#x6bcf;&#x5242;EV-A71&#x75ab;&#x82d7;&#x63a5;&#x79cd;&#x540e;&#x7b2c;4&#x6216;5&#x5929;&#x5bf9;&#x513f;&#x7ae5;&#x76d1;&#x62a4;&#x4eba;&#x8fdb;&#x884c;&#x7535;&#x8bdd;&#x968f;&#x8bbf;&#xff0c;&#x8bb0;&#x5f55;&#x513f;&#x7ae5;&#x63a5;&#x79cd;&#x540e;3 d&#x5185;&#x5c40;&#x90e8;&#x3001;&#x5168;&#x8eab;&#x548c;&#x5176;&#x4ed6;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x53d1;&#x751f;&#x60c5;&#x51b5;&#xff0c;&#x63cf;&#x8ff0;&#x4e0d;&#x540c;&#x7279;&#x5f81;&#x513f;&#x7ae5;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x53d1;&#x751f;&#x60c5;&#x51b5;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> &#x5171;&#x63a5;&#x79cd;&#x75ab;&#x82d7;32 230&#x5242;&#x6b21;&#xff0c;&#x7b2c;1&#x548c;2&#x5242;&#x5206;&#x522b;&#x4e3a;20 191&#x548c;12 039&#x5242;&#x6b21;&#xff0c;3 d&#x5185;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x53d1;&#x751f;&#x7387;&#x5206;&#x522b;&#x4e3a;2.045%&#xff08;413&#x5242;&#x6b21;&#xff09;&#x548c;1.611%&#xff08;194&#x5242;&#x6b21;&#xff09;&#x3002;&#x7b2c;1&#x548c;2&#x5242;&#x5168;&#x8eab;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x5242;&#x6b21;&#x5747;&#x8f83;&#x591a;&#xff0c;&#x5206;&#x522b;&#x4e3a;371&#x548c;175&#x5242;&#x6b21;&#xff0c;&#x53d1;&#x751f;&#x7387;&#x5206;&#x522b;&#x4e3a;1.837%&#x548c;1.454%&#xff1b;&#x5c40;&#x90e8;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x5242;&#x6b21;&#x5747;&#x8f83;&#x4f4e;&#xff0c;&#x5206;&#x522b;&#x4e3a;14&#x548c;2&#x5242;&#x6b21;&#xff0c;&#x53d1;&#x751f;&#x7387;&#x5206;&#x522b;&#x4e3a;0.069%&#x548c;0.017%&#x3002;&#x63a5;&#x79cd;&#x540e;&#x53d1;&#x751f;&#x7684;&#x5c40;&#x90e8;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x4e00;&#x822c;&#x75c7;&#x72b6;&#x8f7b;&#x5fae;&#xff0c;&#x51fa;&#x73b0;3&#x7ea7;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x75c5;&#x4f8b;&#x4ec5;2&#x4f8b;&#xff1b;&#x5168;&#x8eab;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x4e2d;&#xff0c;3&#x7ea7;&#x53ca;&#x4ee5;&#x4e0a;&#x53d1;&#x70ed;&#x75c5;&#x4f8b;&#x4e3a;39&#x4f8b;&#xff0c;&#x5360;&#x603b;&#x53d1;&#x70ed;&#x4f8b;&#x6570;&#x7684;8.2%&#x3002;&#x5c40;&#x90e8;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x4e2d;&#xff0c;&#x4ec5;&#x6709;3&#x4f8b;&#x63a5;&#x79cd;&#x90e8;&#x4f4d;&#x76ae;&#x75b9;&#x548c;2&#x4f8b;&#x7619;&#x75d2;&#x75c5;&#x4f8b;&#x9700;&#x81ea;&#x8d2d;&#x836f;&#x6216;&#x95e8;&#x8bca;&#x6cbb;&#x7597;&#xff0c;&#x5176;&#x4f59;&#x65e0;&#x9700;&#x6cbb;&#x7597;&#xff1b;&#x5168;&#x8eab;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x4e2d;&#xff0c;&#x9664;5&#x4f8b;&#x53d1;&#x70ed;&#x75c5;&#x4f8b;&#x5916;&#xff0c;&#x5176;&#x4f59;&#x75c7;&#x72b6;&#x5747;&#x672a;&#x4f4f;&#x9662;&#x6cbb;&#x7597;&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> &#x513f;&#x7ae5;&#x63a5;&#x79cd;EV-A71&#x75ab;&#x82d7;&#x540e;3 d&#x5185;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x53d1;&#x751f;&#x7387;&#x8f83;&#x4f4e;&#xff0c;&#x4e3b;&#x8981;&#x4e3a;&#x5168;&#x8eab;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#xff0c;&#x4e14;&#x9884;&#x540e;&#x826f;&#x597d;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Hand, foot and mouth disease</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30841663</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.0253-9624.2019.03.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>